Back to search
PIK3CA-Related Overgrowth Spectrum (PROS)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-Related Overgrowth Spectrum (PROS) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-Related Overgrowth Spectrum (PROS) trials you may qualify forThis is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3…
This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth spe…
This study is a multi-center, open-label, single arm, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CYH33…
This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension period…
The purpose of this registration is to list Managed Access Programs (MAPs) related to BYL719, Alpelisib
This is a prospective interventional Phase II multi center study, open label, preceded by a retrospective non-interventional period, to assess the long-term saf…